Clinicopathological findings, prognosis, and Epstein–Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders
Clinicopathological findings, prognosis, and Epstein–Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders
Other iatrogenic immunodeficiency-associated (OIIA) T- and natural killer (NK)-cell lymphoproliferative disorders (TNK-LPDs) are rare in patients with rheumatoid arthritis (RA).
We investigated the clinicopathological characteristics, Epstein–Barr virus (EBV) infection, genetic findings, therapeutic response, and prognostic factors in 21 RA patients with OIIA TNK-LPDs and compared these with those of 39 with OIIA B-cell LPDs (B-LPDs) and 22 with non-OIIA B-LPDs.
Immunohistologically, 11 patients (52%) showed CD4+ T-LPDs, and 7 had a T follicular helper (TFH) phenotype. The other nine patients (43%) showed CD8+ T-LPDs, and the remaining one (5%) had features of CD3+ CD4− CD8− nasal type TNK-cell lymphoma. CD30+, p53+, and CMYC+ atypical lymphocytes were identified in seven (33%), eight (38%), and five (24%) patients, respectively. In situ hybridisation detected EBV-encoded RNA (EBER) + large atypical lymphocytes in five patients (24%). Nine of 17 patients (53%) showed clonal peaks of TCRγ by polymerase chain reaction. Withdrawal of MTX and biologic drugs was effective in 12 patients (57%), and 8 (38%) received chemotherapies. Two patients with TFH+ or EBV+ CD4+ CD30+ large cell peripheral T-cell lymphoma, one with CD8+ systemic anaplastic large cell lymphoma, and two with systemic EBV+ CD8+ T-cell lymphoma of childhood showed a lethal progressive clinical course within 13 months. Moreover, > 500 U/L LDH, large atypical lymphocytes, expression of CD30, p53, and CMYC, and EBER+ atypical lymphocytes were significantly poor prognostic factors for overall survival (p < 0.05). Median interval from RA onset to OIIA TNK-LPDs was 72 months, which was shorter than 166 months in OIIA B-LPDs (p = 0.003). EBV+ atypical and reactive lymphocytes were frequently found in 15 patients with OIIA TNK-LPDs (71%), in 27 with OIIA B-LPDs (69%), and only in 3 with non-OIIA B-LPDs (14%).
OIIA TNK-LPDs occurred in early phase of RA, compared with OIIA B-LPDs, and occasionally showed a lethal progressive clinical course. Detection of OIIA TNK-LPD patients with poor prognostic factors is necessary. EBV infection in immunosuppressed patients due to persistent RA, MTX, and biologic drugs may play a role in forming the tumour microenvironment and lymphomagenesis of TNK-LPDs.
Post-transplant lymphoproliferative disorders (LPDs) are found in recipients with immunosuppressants, and other iatrogenic immunodeficiency-associated (OIIA) LPDs mainly occur in rheumatoid arthritis (RA) patients treated with low-dose methotrexate (MTX), tumour necrosis factor (TNF) inhibitors, and other biologic drugs, and are infrequent in other types of autoimmune disease . The histological types of OIIA LPDs in RA patients are mainly composed of B-cell LPDs (B-LPDs), occasionally Hodgkin lymphoma, and rarely T- and natural killer (NK)-cell LPDs (TNK-LPDs) [1,2,3,4]. OIIA TNK-LPDs are mostly composed of CD8+ T-large granular lymphocytosis/leukaemia (T-LGL), angioimmunoblastic T-cell lymphoma (AITL) with CD4+ T follicular helper (TFH) phenotype, peripheral T-cell lymphoma (PTCL)-not otherwise specified (NOS), or T-LPDs, and rarely of nasal type TNK-cell lymphoma (TNKCL) [5,6,7,8,9]. Approximately 4% of RA patients treated with or without MTX, TNF inhibitors, and other biologic drugs showed clonal expansions of mainly CD8+ and occasionally CD4+ T-LGL . Epstein–Barr virus-encoded RNA (EBER) + atypical lymphocytes are frequently observed in OIIA B-LPDs and Hodgkin lymphoma, but are rarely reported in TNK-LPDs and T-LGL [1, 3, 4, 7, 8]. Furthermore, EBV+ atypical lymphocytes indicated a favourable prognostic factor in patients with OIIA B-LPDs but were not evident in TNK-LPDs [3, 4, 8]. Withdrawal of MTX, TNF inhibitors, and other biologic drugs are effective for the treatment of RA patients with OIIA B- and TNK-LPDs, and additional chemotherapies are also effective in patients without tumour regression [4, 8]. However, a lethal T-cell lymphoma (TCL) has been reported in a few RA patients treated with MTX and biologic drugs [7, 11, 12]. Three RA patients treated with MTX and TNF inhibitors and 22 with inflammatory bowel disease (IBD) receiving TNF inhibitors had hepatosplenic TCL with a lethal progressive clinical course, as recorded in the database of Food and Drug Administration (FDA) adverse event reporting system . MTX, TNF inhibitors, and other biologic drugs may induce profound immunosuppression and possibly lethal lymphomagenesis in RA patients.
In the current study, we subclassified 21 RA patients with OIIA TNK-LPDs into CD4+, CD8+, and CD4− CD8− phenotypes, and identified characteristic histological and immunohistological findings to EBV infection of atypical lymphocytes and scattered lymphocytes in the background, genetic findings, and prognostic factors, which were compared with those of OIIA and non-OIIA B-LPDs. We advocated detection of TNK-LPDs with poor prognostic factors including EBER+ atypical lymphocytes, and examined the etiological role of EBV infection in RA patients with OIIA TNK-LPDs.
Patient selection and clinical findings
Twelve thousand three hundred registered patients with LPDs or lymphomas were reviewed and retrieved retrospectively over the period of 1990 to 2020 at the Department of Pathology, Fukuoka University. Histological classification was performed according to the World Health Organization classification (2017) . We retrospectively reviewed the medical records of the patients who met all the inclusion criteria. The inclusion criteria included patients who met the American College of Rheumatology classification criteria for RA; we selected RA patients who developed LPDs. OIIA LPDs were defined as LPDs occurring in RA patients treated with low-dose MTX, TNF inhibitors, or other biologic drugs [1, 9]. Twenty-one RA patients with OIIA TNK-LPDs, 39 RA patients with OIIA B-LPDs, and 22 RA with non-OIIA B-LPDs were analysed. Human immunodeficiency virus (HIV)-positive patients and human T-lymphotropic virus (HTLV)-1-positive carriers were not included in the current study. Corresponding medical records were reviewed to obtain clinical information, including Ann Arbor stage, treatment, and survival. The criteria of LPD regression were if LPDs in RA patients had shrunk or improved following 4-week withdrawal of MTX, biologic drugs, and immunosuppressants, according to the systemic findings including laboratory data and radiological images, and did not require further treatment with chemotherapy . Diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made using the revised HLH-2004 criteria .
Histology, immunohistology, and detection of EBV
Excised tissue specimens were fixed in 10% formalin to generate formalin-fixed paraffin-embedded (FFPE) samples that were stained with haematoxylin and eosin. For immunohistochemistry, antibodies were applied to the tumour samples using a Leica Bond III-automated stainer (Leica Biosystems, Buffalo Grove, IL, USA), and peroxidase reactions were developed using diaminobenzidine. These antibodies are listed in Table S1. Criteria of small, medium, and large atypical cell sizes were compliant with those of mantle cells, centrocytes, and centroblasts, respectively, in lymphoid follicles. Large-cell TNK-LPDs were characterised by ≥50% large lymphoid cells with distinct nucleoli. Small-cell TNK-LPDs consisted of predominantly small- or medium-sized atypical lymphocytes. For all immunostaining, reactions were considered positive when ≥30% of atypical lymphocytes were positively stained. The TFH phenotype was defined by the expression of at least two of the following five antibodies: PD-1, inducible T-cell co-stimulator (ICOS), BCL6, C-X-C motif chemokine ligand (CXCL)13, and CD10 . Assessments of CMYC+, p53+, or programmed cell death-ligand (PD-L) 1+ atypical lymphocytes and the number of PD-L1+ non-neoplastic cells were performed according to the methods reported in our previous study . The presence of EBV infection was determined by in situ hybridisation of EBER+ nuclear signals in ≥50% of atypical lymphoid cells. For EBER staining, tissue sections were hybridised in a solution of 50% formamide containing fluorescein isothiocyanate-labelled EBER oligonucleotides (Leica). Double-staining of lymphocyte markers and EBER was performed to confirm the presence of EBV+ T or B cells.
Molecular analysis of the T-cell receptor (TCR) γ locus
For polymerase chain reaction (PCR) amplification of the TCRγ locus, DNA was prepared from the FFPE specimens of 17 patients. BIOMED-2 multiplex PCR assays (InVivoScribe Technologies, San Diego, CA, USA) of TCRγ (Bottles A, B; Vγ and Jγ gene rearrangements) were performed using standardised protocols and primers . Following amplification, TCRγ PCR products were analysed using GeneScan (MultiNA; Shimazu Co., Kyoto, Japan) as previously described .
Detection of RHOA G17V mutation by Sanger sequencing
PCR was performed with AmpliTaq gold (Thermo Fisher Scientific, Waltham, MA, USA) using 40 ng genomic DNA, 0.3 μM primers, and 2 μL AmpliTaq gold master mix. A PCR-amplified product of 244 bp, including the codon for the 17th amino acid, was obtained in 12 TLPD patients, and direct sequencing of these products was performed. The coding DNA position 50G > T mutation of the RHOA gene predicted the change of the wild-type G (Gly) to the mutant type V (Val) .
The clinicopathological features of patients with OIIA TNK-LPDs, OIIA B-LPDs, and non-OIIA B-LPDs were compared with Fisher’s exact test or χ2 test. Medians were compared with Wilcoxon rank sum test. For the RA patients with LPDs, progression-free survival (PFS) was calculated from the initial diagnosis date to the first date of disease progression or relapse, and overall survival (OS) was calculated from the initial time of diagnosis to the date of last follow-up or death. PFS and OS curves were generated using the Kaplan–Meier method and analysed by the proportional hazards model. A p-value of < 0.05 was considered statistically significant. Statistical analyses were performed using JMP 10 software (SAS Institute, Cary, NC, USA).
The clinical features and treatments of 11 RA patients with OIIA CD4+ T-LPDs (52%), 9 with CD8+ T-LPDs (43%), and 1 with CD4− CD8− TNK-LPDs (5%) are shown in Tables 1 and 2. The median age of all 21 patients was 64 years, and the male to female ratio was 6 to 15. The median interval from RA onset to TNK-LPDs was 72 months, and the median duration of low-dose MTX therapy was 53 months. Overall, ≥ 300 U/L lactate dehydrogenase (LDH) and ≥ 2000 U/ml of soluble interleukin 2 receptor (sIL2R) titres in sera were detected in 13 TNK-LPD patients (62%) and 11 of the examined 19 (58%), respectively. Extranodal tumour involvement was initially identified in six of nine patients with CD8+ T-LPDs (67%), compared with one with CD4+ T-LPDs (9%) (p = 0.017). Four patients with CD8+ T-LPDs had bone marrow invasion by atypical lymphocytes, and each one had hepatic (Fig. 1) and subcutaneous tumours. In addition to MTX therapy for RA, one patient with TFH+ PTCL (Case No. 3) and another with CD4+ large cell PTCL-NOS (Case No. 8) received TNF inhibitor (adalimumab) or anti-IL6 receptor antibody (Ab) (tocilizumab) and azathioprine. Two patients with CD8+ HLH and subcutaneous panniculitis-like T-LPDs (Case Nos. 18 and 20) received TNF inhibitor (infliximab) or anti-cytotoxic T lymphocyte antigen (CTLA)-4 Ab (abatacept). Sixteen TNK-LPD patients (76%) were classified with advanced clinical stage III or IV.
Histology, immunohistological findings, EBV, and genetic studies
Histologically, the tumours of 9 patients (43%) mainly consisted of large, atypical lymphocytes, and the remaining 12 (57%) were composed of small- and/or medium-sized atypical lymphocytes, as shown in Table 2. In 11 CD4+ T-LPD patients, 7 (Case Nos. 1–7) showed diffuse invasion by CD4+ large or small, atypical lymphocytes with the TFH phenotype (Fig. 2A, 3A). Moderate plasmacytic and histiocytic reactions, vascular reaction, and partly preserved CD20+ B cell nests were found in four patients with small cell TFH+ T-LPDs (Case Nos. 4–7), and no definite nests of neoplastic clear cells were detected (Fig. 2B). Among TFH+ T-LPDs, atypical lymphocytes showed ICOS expression in seven patients (100%, Fig. 3B), PD-1 in six (86%), CXCL13 in four (57%), BCL6 in three (43%), and CD10 in two (29%). The other two patients (Case Nos. 8 and 9) had CD4+ EBER+ large-cell PTCL-NOS with expression of CD30 and CD25 and without the TFH phenotype (Figs. 2C, 3C). The remaining two patients (Case Nos. 10 and 11) showed CD4+ small-cell T-LPDs without the TFH phenotype. In nine patients with CD8+ T-LPDs, one (Case No. 12) had CD3+ EBER−sALCL with expression of CD30, CD25, and TIA1. Two patients (Case Nos. 13 and 14) had CD8+ T-LPDs mainly involving the bone marrow and liver, revealing features of systemic EBV (sEBV) + TCL of childhood with HLH (Fig. 2D, E, 3D, E). The remaining six patients (Case Nos. 15–20) had CD8+ and TIA1+ T-LPDs (Fig. 2F), manifesting T-LGL, bone marrow-involved HLH, nodal small-cell TCL or T-LPDs, and subcutaneous panniculitis-like T-LPDs. The remaining patient (Case No. 21) had CD3+ CD4− CD8− CD56− EBER+ nasal type TNKCL with CD30, CD25, and TIA1 expression in the nasal cavity. CD30+ large, atypical lymphocytes were detected in six CD4+ or CD8+ TCL patients and in one nasal type TNKCL (5%), and the atypical lymphocytes were negative for anaplastic lymphoma kinase (ALK). p53+ atypical lymphocytes were detected in eight patients (38%) (Fig. 3F), and CMYC+ atypical lymphocytes were found in five (24%). PD-L1+ atypical lymphocytes were detected in three patients (14%); one each of CD4+ large-cell PTCL-NOS, sEBV+ CD8+ TCL, and CD4− CD8− nasal type TNKCL. Intense (R3+) reactions of PD-L1+ non-neoplastic cells were detected in the other four T-LPD patients (19%). Many EBER+ CD20− ENBA2− large, atypical lymphocytes were detected in five patients (24%), and four of them were positive for CD30, CD3, and LMP1. Latency type II EBV infection was found in four patients, and the remaining one (Case No. 14) showed latency type I. Scattered EBER+ small CD20+ lymphocytes were detected in the other 10 patients with CD4+ and CD8+ T-LPDs (48%). Among them, some EBER+ CD20+ large lymphocytes were identified in two CD4+ TFH+ patients and one CD8+ T-LPD patient. Fifteen patients (71%) showed TCRβF1+ atypical lymphocytes. Clonal peaks of TCRγ gene Vγ and Jγ regions were detected by PCR in 4 of 10 CD4+ patients (40%), 4 of 6 CD8+ patients (67%), and 1 CD4− CD8− TNK-LPD patient (Fig. 4). RHOA p.G17V mutation by Sanger sequencing was detected in only one TFH+ PTCL patient (Case No. 4) among seven TFH+ T-LPDs (14%), but not in two CD4+ PTCL-NOS and three CD8+ T-LPD patients.
Treatment, prognosis, and prognostic factors
Regression of LPDs by withdrawal of MTX and biologic drugs was detected in 12 patients (57%), including 6 CD4+ T-LPDs, 5 CD8+, and 1 CD4− CD8− TNK-LPD, as shown in Table 1. Chemotherapy including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or pirarubicin, cyclophosphamide, vincristine, and prednisolone (THP-COP), Brentuximab vedotin and etoposide (VP16) were administered to eight patients (38%); among them, five CD4+ T-LPDs and three CD8+ were included. The lethal patient with sEBV+ CD8+ TCL (Case No 13) received only corticosteroid therapy due to their poor clinical condition. Recurrence of T-LPDs was detected in three CD4+ T-LPD patients (14%) (Case Nos 4, 6, 10) and one CD8+ HLH (5%) (Case No 18). Seven patients (33%) died of disease. Among them, two patients with EBV− CD4+ TFH+ PTCL and EBV+ CD4+ CD30+ large-cell PTCL-NOS, one EBV− CD8+ sALCL, and two sEBV+ CD8+ TCLs showed a lethal progressive clinical course within 13 months. Table 3 presents the univariate analysis of prognostic factors in the PFS and OS of 21 TNK-LPD patients. In PFS, ≥ 500 U/L LDH (p = 0.038), large, atypical lymphocytes (p = 0.01), p53+ (p = 0.003), and CMYC+ (p = 0.009) atypical lymphocytes indicated significantly worse prognosis. Five-year OS of 11 CD4+ and 9 CD8+ T-LPD patients was 47 and 65%, respectively. In OS, ≥ 500 U/L LDH (p = 0.037), large, atypical lymphocytes (p = 0.008), CD30+ (p = 0.034), p53+ (p = 0.003), CMYC+ (p = 0.006), and EBER+ (p = 0.043) atypical lymphocytes indicated significantly worse prognosis (Fig. 5).
Clinicopathological differences between RA patients with OIIA TNK-, OIIA-, and non-OIIA B-LPDs
As shown in Table 4, the median interval from RA onset to OIIA TNK-LPDs was 72 months, which was significantly shorter than 166 months in OIIA B-LPDs (p = 0.003) and 177 months in non-OIIA B-LPDs (p = 0.0007). Ten of 19 TNK-LPD patients (53%) showed ≥2000 U/ml of sIL2R, which was significantly higher than six of 28 B-LPDs (21%) (p = 0.025). Sixteen patients with OIIA TNK-LPDs showed advanced clinical stages III and IV, which was significantly higher than 17 of OIIA B-LPDs (44%) (p = 0.032). As well as MTX treatment, TNF inhibitors were administered to five RA patients with OIIA B-LPDs. Infliximab and anti-IL6 receptor Ab (tocilizumab), anti-IL17 Ab (secukinumab), or anti-CTLA-4 Ab (abatacept) were used in each patient. Azathioprine and cyclosporine were also administered to the other three patients. Five TNK-LPD patients (24%) had ≥50% EBER+ atypical lymphocytes, which was significantly lower than 21 of 39 OIIA B-LPDs (54%) (p = 0.031). However, EBER+ atypical lymphocytes and scattered EBER+ small lymphocytes were frequently found in 15 patients with TNK-LPDs (71%) as well as in 27 with OIIA B-LPDs (69%), respectively. Eight patients with TNK-LPDs (38%) received chemotherapy, and 20 with OIIA B-LPDs (51%) received CHOP with rituximab (17 patients) and CHOP or THP-COP (3 patients). Patients with TNK- and OIIA B-LPDs had no prognostic difference in OS (p = 0.083). Five patients with EBER+ TNK-LPDs showed significantly worse prognosis than 21 with EBER+ OIIA B-LPDs (p = 0.0001). EBV+ atypical lymphocytes was a significantly favourable prognostic factor in 39 patients with OIIA B-LPDs (p = 0.015). In 22 RA patients with non-OIIA B-LPDs, EBER+ atypical lymphocytes or scattered EBER+ lymphocytes were noted in 3 patients (14%), which was significantly lower than in those with TNK-LPDs (p = 0.0002). Twenty patients with non-OIIA B-LPDs (91%) received chemotherapies mainly of CHOP with rituximab (10 patients) and CHOP (6 patients), and the 5-year OS was 40%. Patients with TNK-LPDs and non-OIIA B-LPDs had no prognostic difference in OS (p = 0.234).
Seven of our examined 21 RA patients (33%) had OIIA CD4+ TFH+ T-LPDs, and 9 (43%) had complicated CD8+ T-LPDs. EBER+ atypical lymphocytes, scattered EBER+ small lymphocytes, and some large B lymphocytes were detected in six of seven patients with CD4+ TFH+ T-LPDs and in five with CD8+ T-LPDs. A previous study demonstrated that 19 of 28 RA patients with OIIA T-LPDs (68%) showed histological features of CD4+ TFH+ AITL with scattered EBER+ lymphocytes in the background . In RA patients, increased TFH cells and decreased regulatory T cells in the peripheral blood were significantly correlated with the disease activity of RA (p < 0.05), and TFH cells were frequently found in the germinal centres of the involved synovial tissue . In RA patients treated with MTX and biologic drugs, EBV-specific effector memory CD8+ T cells were positively correlated with increased EBV viral load in the peripheral blood . It was suggested that abnormal proliferation of CD4+ TFH cells and CD8+ T cells was due to persistent RA activity and EBV infection found in the immunosuppressive states of RA patients treated with MTX and biologic drugs.
In the current study, five of 21 RA patients with OIIA TNK-LPDs (24%) showed a lethal progressive clinical course within 13 months, having features of TFH+ PTCL, EBV+ CD4+ CD30+ large-cell PTCL-NOS, EBV− CD8+ sALCL, and sEBV+ CD8+ CD30+/− TCLs. Four reported RA patients treated with MTX or MTX and Janus kinase inhibitors suffered from sALCL and EBV+ CD30+ large-cell PTCL, and the three ALK− patients died of the disease within months, while the remaining patient with ALK+ sALCL is alive at 24 months [7, 11, 12, 22]. Parakkal et al.  reported that 3 RA patients treated with MTX and TNF inhibitors for 1.2 to 5 years as well as 22 patients with IBD receiving TNF inhibitors and azathioprine had hepatosplenic TCL in the FDA database, and 2 RA patients died of the disease. The current and previous studies confirmed that RA patients treated with MTX and TNF inhibitors occasionally had complicated T-LPDs with a lethal progressive clinical course.
Our two examined RA patients (Case Nos 15, 16) treated with MTX-complicated CD8+ T-LGL showed indolent clinicopathological features without chemotherapy . Schwaneck et al.  reported that RA patients with mainly CD8+ and occasionally CD4+ T-LGLs mostly showed an indolent clinical course following rituximab (anti-CD20) and anti-IL6 receptor Ab treatment in addition to continuous MTX therapy and/or TNF inhibitors. They suggested that RA-associated T-LGL occurred independently of MTX therapy for RA, and probably due to TNF inhibitors, because of decreasing circulating T-LGLs after cessation of TNF inhibitors. Andrade et al.  reported that one RA patient treated with MTX and TNF inhibitor (etanercept) showed CD4+ CD8+ TCL with HLH and scattered EBV+ cells and received prompt chemotherapy, remaining alive at 24 months. The current study demonstrated that two RA patients (Case Nos. 13, 14) treated with MTX-complicated sEBV+ CD8+ TCL died within 4 months, and another patient treated with MTX and TNF inhibitor (infliximab) (Case No. 18) showed CD8+ T-LPD with features of EBV− HLH. Even in post-transplant LPDs, only a few patients showed sEBV+ CD8+ TCL with a lethal progressive clinical course and CD8+ T-LPDs with features of HLH [24,25,26]. These findings demonstrated that T-LGL with an indolent clinical course was occasionally found, and rare types of lethal and curable EBV+/− CD8+ TCL or T-LPDs with HLH were also detected in RA patients treated with MTX and TNF inhibitors.
The current study demonstrated that clonal peaks of TCRγ were detected in 9 of 17 RA patients with OIIA TNK-LPDs (53%). Only one patient among our examined seven with TFH+ TCL and T-LPDs (14%) showed the RHOA p.G17V mutation. Twenty-one of 47 RA patients with OIIA B-LPDs (45%) showed rearrangements of the immunoglobulin heavy chain (IGH) gene in FFPE specimens by PCR , and the clonality was associated with poor recurrence-free survival (p = 0.05), but not with OS. It was suggested that frequent spontaneous regression of TNK-LPDs as well as B-LPDs by MTX withdrawal in RA patients occurred due to abnormal but not overt neoplastic proliferation of lymphocytes. However, seven RA patients with MTX-associated TNK-LPDs (33%) died of the disease. Notably, ≥ 500 U/L LDH was a significant poor prognostic factor of PFS and OS in RA patients with OIIA TNK-LPDs (p < 0.05). Careful follow-up of serum LDH as well as sIL2R is necessary to detect the progression of OIIA TNK-LPDs in the early-phase of the disease. Histologically, p53 expression in 57 patients with TNKCL was positively correlated with TP53 mutation variant allele frequency, and p53 was a significant poor prognostic factor (p = 0.009) . CMYC expression in patients with aggressive-type adult T-cell leukaemia/lymphoma (ATLL) was significantly higher than that in patients with smouldering and chronic types (p < 0.01) . Because large-sized, CD30+, p53+, CMYC+, and EBER+ atypical lymphocytes were identified as poor prognostic factors in RA patients with OIIA TNK-LPDs (p < 0.05), timely treatment with chemotherapy and biologic drugs is necessary for TNK-LPD patients with a progressive clinical course having some of the identified prognostic factors.
EBER+ atypical lymphocytes and scattered EBER+ lymphocytes were frequently found in the15 examined patients with OIIA TNK-LPDs (71%), and the findings have been also reported in RA patients with OIIA TNK-LPDs (89%) and B-LPDs (63, 45%), but rarely in RA patients with non-OIIA B-LPDs (8%) [3, 4, 8]. Ejima-Yamada et al.  reported that spontaneous regression of LPDs by withdrawal of MTX and biologic drugs was frequently found in 15 of 21 RA patients with OIIA EBV+ B-LPDs (71%), as opposed to none of 17 OIIA EBV− B-LPDs (0%) (p < 0.01). Another recent study demonstrated that high EBV real-time PCR value, improvement of lymphocyte counts in the peripheral blood, and patients with EBER+ cells in the involved tissues were significantly associated with the spontaneous regression of LPDs by withdrawal of MTX and biologic drugs in 34 RA patients with LPDs (p = 0.003, p = 0.036, and p = 0.032, respectively) . These findings highly suggest that tumour microenvironments and lymphomagenesis caused by EBV in RA patients occurred in the immunosuppressive states caused by MTX, THF inhibitors, and other biologic drugs.
Bayda et al.  demonstrated that strong expression of EBV-produced Bam-HI A rightward transcripts (BARTs) and early lytic gene, BNLF2, were frequently found in 14 AITL patients compared with 21 other types of T-, B- and Hodgkin lymphomas by next-generation sequencing for EBV transcriptomes, and the two genes contributed to immune escape and survival of the infected cells. Furthermore, frequent deletion of BART of EBV in peripheral blood mononuclear cells was detected in 10 of 23 patients with TNKCL (44%) and 10 of 14 EBV+ large B-cell lymphoma (71%), but not in 15 with infectious mononucleosis and 32 with post-transplant LPDs . To determine the detailed influence of EBV infection, it is necessary to examine the high expression or deletion of EBV BART and BNLF2 genes in peripheral blood mononuclear cells and tumour tissues between RA patients with OIIA LPDs having regression and no regression of LPDs by withdrawal of MTX and biologic drugs.
This study has some limitations. It was a retrospective study based on small numbers of rare TNK-LPDs in RA patients treated with different types of therapies for LPDs. Hence, it was difficult to confirm the definitive prognostic factors and etiological roles of EBV in TNK-LPDs of RA patients.
We investigated the clinicopathological characteristics and prognostic factors of 21 RA patients with OIIA TNK-LPDs. Immunohistologically, seven CD4+ TLPD patients (33%) had TFH+ atypical lymphocytes, nine (43%) showed CD8+ T-LPDs, and five (24%) had EBER+ large, atypical lymphocytes. Two patients with TFH+ and EBV+ CD4+ CD30+ PTCL and three with CD8+ ALK− sALCL and sEBV+ CD8+ TCL showed a lethal progressive clinical course within 13 months. Furthermore, ≥ 500 U/L LDH, large, atypical lymphocytes, and CD30, p53, CMYC, and EBER expression in atypical lymphocytes were identified as significant poor prognostic factors for OS (p < 0.05). Detection of OIIA TNK-LPDs with poor prognostic factors is required to improve patient outcome. EBER+ atypical and reactive lymphocytes were found in the 15 patients with TNK-LPDs (71%) as well as in 27 of the examined 39 OIIA B-LPDs (69%) but was rare in 22 non-OIIA B-LPDs (14%). EBV infection in the immunosuppressive state resulting from persistent RA and treatment with MTX, TNF inhibitors, and other biologic drugs may play a role in forming the tumour microenvironment and lymphomagenesis of TNK-LPDs.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Angioimmunoblastic T-cell lymphoma
Anaplastic large cell lymphoma
Anaplastic lymphoma kinase
B lymphoproliferative disorders
C-X-C motif chemokine ligand
Cytotoxic T lymphocyte antigen
EBV-associated encoded RNA
Inducible T-cell co-stimulator
Large granular lymphocytosis/leukaemia
Not otherwise specified
Other iatrogenic immunodeficiency-associated
Peripheral T-cell lymphoma
Soluble interleukin-2 receptor
T follicular helper
Tumour necrosis factor
Swerdlow S, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised. 4th ed. Lyon: IARC Press; 2017.
Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. and the investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France. Blood. 2002;99(11):3909–15. https://doi.org/10.1182/blood.v99.113909.
Yamada K, Oshiro Y, Okamura S, Fujisaki T, Kondo S, Nakayama Y, et al. Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders. Histopathol. 2015;67(1):70–80. https://doi.org/10.1111/his.12627.
Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43(7):869–84. https://doi.org/10.1097/PAS.0000000000001271.
Hatachi S, Kunitomi A, Aozasa K, Yagita M. CD8+ T-cell lymphoproliferative disorder associated with Epstein−Barr virus in a patient with rheumatoid arthritis during methotrexate therapy. Mod Rheumatol. 2010;20(5):500–5. https://doi.org/10.1007/s10165-010-0300-z.
Hatanaka K, Nakamura N, Kojima M, Ando K, Irie S, Bunnno M, et al. Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract. 2010;206(1):9–13. https://doi.org/10.1016/j.prp.2009.03.005.
Kondo S, Tanimoto K, Yamada K, Yoshimoto G, Suematsu E, Fujisaki T, et al. Mature T/NK-cell lymphoproliferative disease and Epstein−Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch. 2013;462(4):399–407. https://doi.org/10.1007/s00428-013-1389-1.
Satou A, Tabata T, Miyoshi H, Kohno K, Suzuki Y, Yamashita D, et al. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype; clinicopathological analysis of 28 cases. Mod Pathol. 2019;32(8):1135–46. https://doi.org/10.1038/s41379-019-0264-2.
Satou A, Tsuzuki T, Nakamura S. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders with a T- or NK-cell phenotype. J Clin Exp Hematopathol. 2019;59(2):56–63. https://doi.org/10.3960/jslrt.19013.
Schwaneck EC, Renner R, Junker L, Einsele H, Gadeholt O, Geissinger E, et al. Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis. A comprehensive analysis of 529 Patients. Arth. Rheumatol. 2018;70(12):1914–22. https://doi.org/10.1002/art.40654.
Gru AA, Williams E, Junkins-Hopkins JM. An immune suppression-associated EBV-positive anaplastic large cell lymphoma with a BRAF V600E mutation. Am J Surg Pathol. 2019;43(1):140–6. https://doi.org/10.1097/PAS.0000000000001174.
Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, et al. Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Med Oncol. 2009;26(1):1–9. https://doi.org/10.1007/s12032-008-9069-8.
Basha BM, Bryant SC, Rech KL, Feldman AL, Vrana JA, Shi M, et al. Application of a 5 marker panel to the routine diagnosis of peripheral T-cell lymphoma with T-follicular helper phenotype. Am J Surg Pathol. 2019;43(9):1282–90 https://doi.org/10.1097/PAS.0000000000001315.
Wang Z, Kimura S, Iwasaki H, Takase K, Oshiro Y, Gamachi A, et al. Clinicopathological findings of systemic Epstein-Barr virus-positive T-lymphoproliferative diseases in younger and older adults. Diag Pathol. 2021;16(1):48. https://doi.org/10.1186/s13000-021-01107-1.
van Dongen JJ, Langerak AW, Brüggemann M, Evans PAS, Hummel M, Lavender FL, et al. Design and standardisation of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations. Leukemia. 2003;17(12):2257–317. https://doi.org/10.1038/sj.leu.2403202.
Nagao R, Kikuchi YY, Carreras J, Kikuchi T, Miyaoka M, Matsushita H, et al. Clinicopathologic analysis of angioimmunoblastic T-cell lymphoma with or without RHOA G17V mutation using formalin-fixed paraffin-embedded sections. Am J Surg Pathol. 2016;40(8):1041–50. https://doi.org/10.1097/PAS.0000000000000651.
Cao G, Wang P, Cui Z, Yue X, Chi S, Ma A, et al. An imbalance between blood CD4+ CXCR5+ Foxp3+ Tfr cells and CD4+ CXCR5+ Tfh cells may contribute to the immunopathogenesis of rheumatoid arthritis. Mol Immunol. 2020;125(9):1–8. https://doi.org/10.1016/j.molimm.2020.06.003.
Lunemann JD, Frey O, Eidner T, Bajer M, Roberts S, Sashihara J, et al. Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol. 2008;181(2):991–1000. https://doi.org/10.4049/jimmunol.181.2.991.
Andrade XA, Fuentes HE, Oramas DM, Mann H, Kovarik P. Iatrogenic T-cell lymphoma with associated hemophagocytic lymphohistiocytosis in a patient with long-standing rheumatoid arthritis. Case Rep Hematol. 2018;11(1):1–4. https://doi.org/10.1155/2018/8097965.
George TI, Jeng M, Berquist W, Cherry AM, Link MP, Arber DA. Epstein–Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation. Pediatr Blood Cancer. 2005;44(3):270–6. https://doi.org/10.1002/pbc.20231.
Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Nino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein−Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20–8. https://doi.org/10.1111/ejh.12116.
Huang H-S, Liao C-K, Liu T-T, You H-L, Wang M-C, Huang WT. TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression. Hum Pathol. 2018;80(10):145–51. https://doi.org/10.1016/j.humpath.2018.05.026.
Mihashi Y, Mizoguchi M, Takamatsu Y, Ishitsuka K, Iwasaki H, Koga M, et al. C-MYC and its main ubiquitin ligase, FBXW7, influence cell proliferation and prognosis in adult T-cell leukemia/lymphoma. Am J Surg Pathol. 2017;41(8):1139–49. https://doi.org/10.1097/PAS.0000000000000871.
Ejima-Yamada K, Oshiro Y, Okumura FT, Kondo S, Nakayama Y, Suematsu E, et al. Epstein−Barr virus infection and gene promoter hypermethylation in in rheumatoid arthritis patients with methotrexate-associated B-cell lymphoproliferative disorders. Virchows Arch. 2017;470(2):205–15. https://doi.org/10.1007//s00428-016-2030-x.
Kitamura N, Sugiyama K, Nagasawa Y, Hamaguchi M, Kobayashi H, Takei M. Involvement of Epstein-Barr virus in the development and spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2022;40(7):1330–5. https://doi.org/10.55563/clinexprheumatol/lgfbtq.
Bayda N, Tilloy V, Chaunavel A, Bahri R, Halabi MA, Feuillard J, et al. Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas. Cancers. 2021;13(4):610. https://doi.org/10.3390/cancers13040610.
Okuno Y, Murata Y, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein–Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4(3):404–13. https://doi.org/10.1038/s41564-018-0334-0.
We are grateful to Tomomi Okabe and Tomoko Fukushige for their technical assistance with the immunohistochemical and genetic analyses. We thank H. Nikki March, PhD, from Edanz (https://jp.edanz.com/ac), for editing a draft of this manuscript.
This study was supported in part by a Grant-in-Aid for Scientific Research (17 K08732) from the Ministry of Education, Science, and Culture of Japan.
Authors and Affiliations
Graduate School of Medical Sciences, Division of Pathomorphology, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 8140180, Japan
Shoichi Kimura, Ziyao Wang & Morishige Takeshita
Department of Pathology, Faculty of Medicine, and Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 8140180, Japan
Shoichi Kimura, Ziyao Wang & Morishige Takeshita
Department of Pathology, Matsuyama Red Cross Hospital, 1 Bunkyo-cho, Matsuyama, 7910000, Japan
Department of Haematology, Clinical Research Centre, National Hospital Organization Kyushu Medical Centre, 1-8-1 Jigyohama, Chuo-ku, Fukuoka, 8108563, Japan
Hiromi Iwasaki & Masanori Kadowaki
Department of Hematology, Faculty of Medicine, Oita University, Idaigaoka, Hazama-machi, Yufushi, Oita, 8795593, Japan
Department of Pathology, Faculty of Medicine, Oita University, Idaigaoka, Hazama-machi, Yufushi, Oita, 8795593, Japan
Department of Otolaryngology, Faculty of Medicine, and Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 8140180, Japan
Department of Pathology, Clinical Research Centre, National Hospital Organization Kyushu Medical Centre, 1-8-1 Jigyohama, Chuo-ku, Fukuoka, 8108563, Japan
Department of Internal Medicine, Division of Medical Oncology, Hematology and Infectious Disease, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 8140180, Japan
S.Kimura, Y.O., and M.T. designed and performed the research. Y.O., T.D., S. Kawauchi, and Z.W. collected and summarised the pathological data. T.S. conducted the statistical analyses. H.I., M.K., M.O., and Y.T. administered the treatments and collected the clinical data. S.Kimura. and M.T. wrote the manuscript. All authors read and approved the final manuscript.
The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the ethics committee of the Faculty of Medicine Fukuoka University (U-20-05-002). The research title was ‘Analysis of EBV+ T/NK cell lymphoma’, which was accepted on May 20th, 2020. Due to the retrospective and non-invasive study designs, the ethical review board approved a waiver of written consent to use the specimens of lymphoproliferative disorders.
Consent for publication
The authors declare they have no significant relationships with, or financial interests in, any commercial activities pertaining to this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Kimura, S., Oshiro, Y., Iwasaki, H. et al. Clinicopathological findings, prognosis, and Epstein–Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders.
BMC Cancer22, 1342 (2022). https://doi.org/10.1186/s12885-022-10358-0